Compare Enveric Biosciences Inc (ENVB) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs VF Corp — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while VF Corp trades at $14.52 (market cap $5.65B). The key difference: VF Corp is far larger — about 844.5× Enveric Biosciences Inc's market cap, and VF Corp pays a 2.5% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and VF Corp for 64 Days on average.
| ENVB | VFC | |
|---|---|---|
Market Cap | $6.69M | $5.65B |
Volume | 41,141 | 6,542,273 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $21.55 |
52-Week Low | $1.27 | $12.62 |
Typical Hold Time | 14 Days | 64 Days |
Enterprise Value | -$1.60M | $9.94B |
Dividend Yield | — | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
VFC trades at $14.53, up 0.55% with a bullish technical signal from moving averages. The company reported mixed quarterly results, beating in Q4 2025 but missing in subsequent quarters. Revenue declined from $11.8B in 2022 to $9.5B in 2025, with net losses in recent years. Analyst consensus shows 41% buy ratings with an $18.33 price target, while the stock faces execution risks from Vans brand weakness despite stronger Outdoor segment performance.
The outlook remains cautious with valuation appearing reasonable (P/E 20.84, P/S 0.6) but dependent on successful turnaround execution. Key risks include persistent Vans weakness, high debt levels, and competitive pressures. Upside potential exists if management can stabilize revenue and improve profitability, but investors face significant execution uncertainty in the apparel sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
